

SFPT | 2017



Société Française de
Pharmacologie et de Thérapeutique

ROUEN | Faculté de Médecine-Pharmacie | 19-21 avril

21^e congrès

de la Société Française
de Pharmacologie et de Thérapeutique

PROGRAMME



SFPT | 2017

SOCIÉTÉS ET COMITÉS	4
MOT DE BIENVENUE	5
PROGRAMME EN UN COUP D'ŒIL	6-7
PROGRAMME SCIENTIFIQUE	8-27
- Mercredi 19 avril.....	8-16
- Jeudi 20 avril.....	17-24
- Vendredi 21 avril.....	25-27
LISTE DES POSTERS	28-33
INFORMATIONS PRATIQUES	34-35
NOTES	36-38
REMERCIEMENTS	39

SOCIÉTÉS & COMITÉS

CONSEIL D'ADMINISTRATION

Silvy LAPORTE

Présidente de la SFPT

- Chantal BARIN-LE GUELLEC
- Régis BORDET
- Pascal BOUSQUET
- François DAUPHIN
- Jean DOUCET
- Sébastien FAURE
- François GUEYFFIER
- Jean-Sébastien HULOT
- Véronique LAMARQUE-GARNIER
- Claire LE JEUNNE
- Mathieu MOLIMARD
- Jean Louis MONTASTRUC
- Stéphane MOULY
- Catherine SGRO
- Christian THUILLEZ

COMITÉ LOCAL D'ORGANISATION

- Jean DOUCET
- Vincent RICHARD
- Fabienne TAMION
- Christian THUILLEZ

CONSEIL SCIENTIFIQUE

Régis BORDET

Président du Conseil Scientifique

- Laurence DAULHAC-TERRAIL
- Pierre-Olivier GIRODET
- Cyril GOUDET
- Karine LACUT
- Silvy LAPORTE
- Véronique LEBLAIS
- Patrick ROSSIGNOL
- Matthieu ROUSTIT
- Françoise STANKE-LABESQUE
- Céline VERSTUYFT

Mot de bienvenue

Chers amis, chers collègues,

Soyez les bienvenus à Rouen où nous avons l'honneur et la joie de vous accueillir pour ce 21^e congrès de la SFPT.

Comme chaque année, de nombreux sujets seront abordés, mettant en valeur les travaux de qualité des groupes de travail de la Pharmacologie et de la Thérapeutique françaises.

Cette année sera l'occasion de traiter de thèmes d'actualité dont l'impact sociétal dépasse le strict cadre de la recherche.

Ce sera aussi l'occasion d'échanges et de communications en lien avec d'autres sociétés savantes (Société Francophone du Diabète, Société Française d'Alcoologie, Groupe de Réflexion sur la Recherche Cardio-Vasculaire).

Nous avons fait en sorte que ce congrès rouennais soit riche d'échanges scientifiques et de convivialité.

Très cordialement.

Jean Doucet, Vincent Richard, Fabienne Tamion, Christian Thuillez.

MERCREDI 19 AVRIL

10h30 - 12h30	Baclofène : entre science et passion, où en sommes-nous? AMPHI 500	Atelier DPC : Interactions médicamenteuses et médicaments-aliments en pratique clinique AMPHI 210 A	Atelier DPC : Interprétation des méta-analyses pour la construction des stratégies thérapeutiques AMPHI 210 B
12h30 - 13h00	Pause déjeuner et visite des stands		
13h00 - 13h30	Ouverture du Congrès AMPHI 500		
13h30 - 15h00	Pharmaco-Surveillance AMPHI 500	Pharmacologie moléculaire et pré-clinique AMPHI 210 A	Pharmacologie clinique, méthodologie AMPHI 210 B
15h00 - 16h30	Happy Hour Posters Pause café et visite des stands		
16h30 - 18h00	Pharmacologie Cardiovasculaire AMPHI 210 A	Neuro-Psycho-Pharmacologie AMPHI 110	Actualités sur le médicament et actualités thérapeutiques AMPHI 210 B
18h00 - 19h30	Réunion CNPM AMPHI 210 A	Réunion AEPFP AMPHI 210 B	Réunion APNET AMPHI 110

JEUDI 20 AVRIL (Matin)

8h30 - 10h00	Diabète AMPHI 500	Journée Nationale des CIC AMPHI 110
10h00 - 10h30	Pause café et visite des stands	
10h30 - 11h30	Diabète AMPHI 500	
11h30 - 12h30	Table ronde : Quelle responsabilité juridique et éthique pour les professionnels du médicament ? AMPHI 500	

JEUDI 20 AVRIL (Après-midi)

13h00 - 14h00	Sujets d'actualités AMPHI 500		
14h00 - 15h00	Actualités sur le médicament AMPHI 210 A	Communications libres et Prix de Thèse AMPHI 210 B	Journée Nationale des CIC AMPHI 110 
15h00 – 16h30	Assemblée Générale de la SFPT - AMPHI 210 B		
16h30 - 18h00	Traitements pro et anti-angiogéniques AMPHI 210 A	STP – Personnalisation des traitements AMPHI 210 B	
18h00 - 19h30	Happy Hour Posters	Conférence Grand Public AMPHI 500	
20h00	Soirée du Congrès		

VENDREDI 21 AVRIL

08h00 – 09h00	Réunion REVISE <i>AMPHI 110</i>		
09h00 - 10h30	Sclérose en Plaques <i>AMPHI 210 A</i>		Pharmaco-Surveillance <i>AMPHI 210 B</i>
10h30 - 11h00	Pause café et visite des stands		
11h00 - 12h00	Pharmacologie clinique / Méthodologie <i>AMPHI 210 A</i>	Communications libres <i>AMPHI 110</i>	STP, Personnalisation des traitements <i>AMPHI 210 B</i>
12h00 - 12h15	Présentation des prix de la SFPT <i>AMPHI 210 A</i>		

MERCREDI 19 AVRIL

10h30 – 12h30 Amphi 210A **SESSION VALIDANT DPC**

Atelier DPC (sur inscription) : Interactions médicamenteuses et médicaments-aliments en pratique clinique

NB : Pour valider cet atelier, les participants doivent aussi assister à **2 sessions d'1h30** sur le thème de la iatrogénie médicamenteuse, au choix parmi ces 3 sessions : " Pharmaco-Surveillance" du mercredi après-midi, "STP-Personnalisation des traitements" du jeudi après-midi, "Pharmaco-Surveillance" du vendredi matin.

▪ Modérateur : Stéphane MOULY (Paris)

- 10h30 Mécanismes et conséquences des interactions médicamenteuses - Haleh BAGHERI (Toulouse)
- 11h00 Les interactions Médicaments-Alimentation se limitent-elles au jus de pamplemousse ? - Stéphane MOULY (Paris)
- 11h30 Place de la pharmacogénomique et des dosages plasmatiques dans la prise en charge des Interactions médicamenteuses ? - Céline VERSTUYFT (Paris)
- 12h00 Discussion - Questions diverses

10h30 - 12h30 Amphi 210B **SESSION VALIDANT DPC**

Atelier DPC (sur inscription) : Interprétation des méta-analyses en réseau pour la construction des stratégies thérapeutiques

NB : Pour valider cet atelier, les participants doivent aussi assister aux **2 sessions d'1h30** suivantes, sur le thème de la méthodologie : session "Pharmacologie clinique, méthodologie" du mercredi après-midi et session "Diabète" du jeudi matin.

▪ Modérateur : Michel CUCHERAT (Lyon)

- 10h30 Principe des comparaisons indirectes - François GUEYFFIER (Lyon)
- 11h00 Condition de validité des comparaisons indirectes - Michel CUCHERAT (Lyon)
- 11h30 Méta-analyse en réseau : principe, notion d'inférence Bayésienne - Michel CUCHERAT (Lyon)
- 12h00 Interprétation des résultats, stratégie de présentation des résultats - Guillaume GRENET (Lyon)

10h30 - 12h30 Amphi 500

Symposium sous l'égide de la SFPT et de la Société Française d'Alcoologie
Baclofène : entre science et passion, où en sommes-nous ? Résultats des études récentes et données de sécurité du baclofène dans le trouble de l'usage d'alcool

- Modérateurs : Maurice DEMATTEIS (Grenoble), François PAILLE (Nancy)
- Présidents : Régis BORDET (Lille) et Mickael NAASSILA (Amiens)

Conférences invitées

- 10h30 **ALPADIR** : étude multicentrique évaluant le maintien de l'abstinence et la réduction de consommation après sevrage - Michel REYNAUD (Paris)
- 11h00 **BACLOVILLE** : étude pragmatique en libéral évaluant l'abstinence et la réduction de consommation - Philippe JAURY (Paris)



- 11h30 Que disent les études internationales récentes ? - Nicolas SIMON (Marseille)
- 12h00 **BACLOPHONE**, CAMTEA et ANSM : les données de sécurité de l'utilisation du baclofène - Benjamin ROLLAND (Lille)

13h00 – 13h30 Amphi 500
Ouverture du Congrès

13h30 - 15h00 Amphi 500
Pharmaco-Surveillance

▪ Modérateurs : Annie Pierre JONVILLE-BERA (Tours), Antoine PARIENTE (Bordeaux)

Conférence invitée

- 13h30 Immunothérapie anticancéreuse et effets indésirables dysimmunitaires - Samia MOURAH (Paris)

Communications libres

- 14h00 CO-001 - Detection of serious adverse drug reactions in public hospitals in Brittany: first results of the BREIZH project - Marie-Noëlle OSMONT (Rennes)
- 14h10 CO-002 - Cardiac failure adverse drug reaction with protein kinase inhibitors: from pharmacovigilance to basic pharmacology - Emilie PATRAS DE CAMPAIGNO (Toulouse)
- 14h20 CO-003 - Assessing the relationship between the use of NSAIDs for pain or fever and serious bacterial infection - Annie-Pierre JONVILLE-BÉRA (Tours)
- 14h30 CO-004 - DRESS syndrome with vemurafenib and cobimetinib: role of cobimetinib? - Gwenaëlle VEYRAC (Nantes)
- 14h40 CO-005 - Lipid-lowering drugs and cataract - Julien BEZIN (Bordeaux)
- 14h50 CO-006 - Androgen-Deprivation Therapy and Cardiovascular Risk (ADTCR): A nationwide population-based cohort study - Lucie-Marie SCAILTEUX (Rennes)

13h30 - 15h00 Amphi 210B
Pharmacologie clinique, méthodologie

• Modérateurs : Jehan-Michel BEHIER (Paris), Stéphane MOULY (Paris)

Conférence invitée

- 13h30 Les sous-groupes dans les essais - Michel CUCHERAT (Lyon)

Communications libres

- 14h00 CO-013 - Population pharmacodynamic analysis of effect of three increasing doses of fludrocortisone on phenylephrine-mean arterial pressure dose-response relationship in healthy volunteers - Karima HAMMAS (Rennes)
- 14h10 CO-014 - Is there a relationship between tranexamic acid concentrations and blood loss after total hip arthroplasty? Pharmacokinetics/pharmacodynamics analysis of the PORTO study - Julien LANOISELÉE (Saint-Etienne)
- 14h20 CO-015 - Efficacy of targeted therapies metastatic colorectal cancer: systematic review and meta-analysis - Amandine GOUVERNEUR (Bordeaux)

MERCREDI 19 AVRIL

- 14h30
- CO-016 - Suboptimal Cotrimoxazole prophylactic concentrations in children
- Claire PRESSIAT (Paris)
- 14h40
- CO-017 - Evaluation and optimization of cefotaxime dosing regimen in neonates and young infants: a population and developmental pharmacokinetic analysis - Stéphanie LEROUX (Paris)
- 14h50
- CO-018 - Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: an effect size meta-analysis - Charles KHOURI (Grenoble)

13h30 - 15h00 Amphi 210A

Pharmacologie moléculaire et pré-clinique

- Modérateurs : Cyril GOUDET (Montpellier), Véronique LEBLAIS (Chatenay-Malabry)

Conférence invitée

- 13h30
- Pharmacologie des connexines - Bruno GUIARD (Toulouse)

Communications libres

- 14h00
- CO-007 - Cannabinoids' effects on cardiac repolarization: a comparative ex vivo study between THC and synthetic cannabinoids (SCs) in rabbit ventricular strip - Laura TESTARD (Caen)
- 14h10
- CO-008 - Influence of cell density on the β -adrenoceptor/cAMP/PDE signalling pathway in vascular smooth muscle cells - Milia BELACEL-OUARI (Châtenay-Malabry)
- 14h20
- CO-009 - The calcium channels as new targets of methylglyoxal-induced cardiac dysfunction and the protective effects of metformin - Hélène PEYRET (Reims)
- 14h30
- CO-010 - Effects of 5/6 nephrectomy in mice: comparaison between 129/Sv and C57BL/6 strain - Mouad HAMZAOUI (Rouen)
- 14h40
- CO-011 - Empagliflozin, a selective sodium glucose co-transporter 2 inhibitor, prevents the high glucose-induced senescence in cultured endothelial cells: Role of NADPH oxidase and cyclooxygenases - Sonia KHEMAIS (Strasbourg)
- 14h50
- CO-012 - Adenosine-mediated antiapoptotic effect of ticagrelor against hypoxia-reoxygenation injury in endothelial cells - Catherine FELIU (Reims), Zoubir DJERADA (Reims)

15h00 – 16h30 Happy Hour Posters RDC

Zone jaune

Modérateurs: Théodora ANGOULVANT (Tours)
Pascal BOUSQUET (Strasbourg)

- PM1-001 - T cells contribute to cardiac lymphatic remodeling post-MI - Mahmoud HOUSSARI (Rouen)
- PM1-002 - Brugada syndrome after treatment with lamotrigine - Roya NILI (Paris)
- PM1-003 - Association between endothelial dysfunction and brain BDNF levels in a rat model of arthritis - Martin PEDARD (Dijon)
- PM1-004 - No common SNP associated to Sotalol-induced IKr inhibition - Joe-Elie SALEM (Paris)
- PM1-005 - Vasorelaxing effect of a TrkB receptor agonist on mesenteric arteries - Perle TOTOSON (Besançon)
- PM1-006 - Effect of estrogen on cardiac function and oxidative stress in renovascular hypertensive rats - Adili ABUDOUREHEMAN (Urumqi - Chine)
- PM1-007 - Effect of cardiac ischemia/reperfusion in adjuvant-induced arthritis in rats - Johnny MORETTO (Besançon)
- PM1-008 - Protective effects of Matricaria recutita decoction extract on human neutrophils ROS production, alcohol-induced haematological parameters changes and erythrocytes oxidative stress in rat - Hichem SEBAI (Béja - Tunisie)

Zone orange

Modérateurs: François GUEYFFIER (Lyon)
Matthieu ROUSTIT (Grenoble)

- PM1-009 - SGLT-2 inhibitors and severe ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database – Jean-Luc FAILLIE (Montpellier)
- PM1-010 - Geographic Differences in Cardiovascular Effects of Recently Marketed Antidiabetic Drugs: a Sub-Group Meta-Analysis - Matthieu ROUSTIT (Grenoble)
- PM1-011 - Protocol of GLUcose COntrol Safety & Efficacy in type 2 Diabetes, a NETWORK meta-analysis (GLUCOSE DINET protocol) - Guillaume GRENET (Lyon)
- PM1-012 - Non-Insulin Glucose Lowering Drugs and risk of trauma: a nested case control study from French Health Insurance Database. - Mickael ARNAUD (Bordeaux)
- PM1-013 - Insulin glargine 300 U/mL (Gla-300) provides more stable and more evenly distributed steady-state PK/PD profiles compared with insulin degludec in type 1 diabetes - Ronan ROUSSEL (Paris)
- PM1-014 - Influence of Outdoor air pollution on pediatric asthma emergency department visits – Frantz FOISSAC (Paris)
- PM1-015 - Quantification of therapeutic antisense oligonucleotides with liquid chromatography – high resolution mass spectrometry – Stanislas GRASSIN-DELYLE (Montigny Le Bretonneux)
- PM1-016 - Tacrolimus intracellular concentrations in periperal mononuclear blood cells of liver transplant recipients: preliminary results - Antoine PETITCOLLIN (Rennes)

Zone rose

Modérateurs: Isabelle LACROIX (Toulouse)
Nathalie MASSY (Rouen)

- PM1-017 - Lactation suppression: what are the actual practices in France? - Nathalie PARET (Lyon)
- PM1-018 - Valproic acid (DEPAKINE), a new mediated scandal in France, a step towards more transparency - Marie BOULEAU (Lyon)
- PM1-019 - Teratogenic risk of macrolides during the first trimester of pregnancy: a study with two complementary approaches within the EFEMERIS database – Agnès SOMMET (Toulouse)
- PM1-020 - Self-medication during pregnancy: a survey at the maternity hospital of Nantes - Anne-Lise RUELLAN (Nantes)
- PM1-021 - Use of digestive disorders medications by children exposed in utero to atropinic drugs - Justine BÉNÉVENT (Toulouse)
- PM1-022 - Impact of drug exposure on voluntary termination of pregnancy request: a survey in Southwest France – Christine DAMASE-MICHEL (Toulouse)
- PM1-023 - First data about nefopam exposure during pregnancy - Christine DAMASE-MICHEL (Toulouse)
- PM1-024 - Selective serotonin re-uptake inhibitors (SSRIs) in utero exposure and prolonged QT interval: two cases of newborns - Julie LEBRUN (Montpellier)

Zone rouge

Modérateurs: Rodolphe GARRAFFO (Nice)
Florian LEMAITRE (Rennes)

- PM1-025 - Is the recommended dose of Micafungin suitable in every critically ill patient? – Franck SAINT-MARCOUX (Limoges)
- PM1-026 - Does age have an impact on medical treatment in infective endocarditis? - Charlotte MARCHAND (Rouen)
- PM1-027 - Plasma concentrations of amoxicillin and ceftazidime administered by continuous infusion according to the renal function - Matthieu GRÉGOIRE (Nantes)
- PM1-028 - Consumption of antiretroviral used in HIV and associated expenditures in Europe during the last ten years: Impact of recent generic antiretroviral on cost reduction - Joseph RWAGITINYWA (Toulouse)
- PM1-029 - CYP450 3A4 inhibition: differences according to the involved macrolide? – Agnès SOMMET (Toulouse)
- PM1-030 - High dose of efavirenz (25 mg/kg) in children under 3 years old - Claire PRESSIAT (Paris)
- PM1-031 - Influence of nebulized colimicyn dilution on the pharmacokinetics of colistin and colistimethate sodium in critical ill patients suffering from ventilator associated multiresistant germs pneumonia - Kevin BIHAN (Paris)
- PM1-032 - Safety profile of pyremathamine and sulfadoxine combination - Adélaide MIGUEL (Reims)

Zone bleue

Modérateurs: Céline EIDEN (Montpellier)
Valérie GIBAJA (Nancy)

- PM1-033 - Prescription patterns of analgesic drugs in opioid maintained patients (TOXIDOL 4 study) – Nicolas AUTHIER (Clermont-Ferrand)
- PM1-035 - Paracetamol: knowledge, use and potentiel overdosage in urban patients consulting their general practitioner – Nadine PETITPAIN (Nancy)
- PM1-036 - Assessment of opioid analgesics addiction in patients with non-cancerous chronic pain followed at a center for pain assessment and treatment using a substance use disorders questionnaire derived from DSM-V criteria - Céline EIDEN (Montpellier)
- PM1-037 - Prevalence and characteristics of chronic pain in opioids maintained patients in France (TOXIDOL 3 study) – Nicolas AUTHIER (Clermont-Ferrand)
- PM1-038 - How Safe are Synthetic Cannabinoids ? - Juliana TOURNEBIZE (Nancy)
- PM1-039 - Non-medical Use of Fentanyl Patches: Review of the Available Literature - Juliana TOURNEBIZE (Nancy)
- PM1-040 - Factors associated with toxicity in methadone treated patients with a one year follow-up (the ANRS Methaville study) - Romain TORRENTS (Marseille)
- PM2-015 - Involvement of addictovigilance in a program of detection of adverse drug events at an Emergency department (URGEIM) – Hélène PEYRIERE (Montpellier)

Zone verte

Modérateurs: Jean-Claude ALVAREZ (Paris)
Gwenaëlle VEYRAC (Nantes)

- PM1-041 - Incidence of encephalopathy and associated risk factors in two different ifosfamide formulations: a retrospective bicentric study - Chouki CHENAF (Clermont-Ferrand)
- PM1-042 - Does the brand-name drug Ifosfamide EG® generate more encephalopathy in adults that Holoxan®? Study at the grenoble university hospital - Gwendal VIARD GAUDIN (Grenoble)
- PM1-043 - Recurring acute sinus bradycardia in a woman treated by a low-dose cytarabine chemotherapy regimen: a case report - Cecile BASSELIN (Lyon)
- PM1-044 - Vasculitis during chemotherapy with erlotinib: case report, review of literature and analysis in the French pharmacovigilance database - Faustine VIDIL (Paris)
- PM1-045 - Myositis case during chemotherapy with docetaxel - Faustine VIDIL (Paris)
- PM1-046 - Cancer immunotherapy by anti-PD-1: a therapeutic efficacy with immune adverse effects. A 10 months Follow up of Pembrolizumab after of marketing authorization in France – Antoine COQUEREL (Caen)
- PM1-047 - Safety of anti PD1 in the treatment of melanoma: a survey in 90 patients treated in a French university hospital - Nagham KHANAFER (Lyon)
- PM1-048 - Adverse events related to nivolumab in non-small cell lung cancer (NSCLC) : a retrospective observational study - Marion SASSIER (Caen)

Zone beige

- Modérateurs: Bruno LAVIOLLE (Rennes)
Célia LLORET-LINARES (Paris)
- PM1-049 - Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology - Alexandre QUILLET (Poitiers)
 - PM1-050 - Survey on iatrogenic events, adverse drug reactions reporting and pharmacovigilance knowledge among general practitioners (GPs) in the Limousin region - Lucie LAVAUD (Limoges)
 - PM1-051 - Simplified pharmacovigilance reporting in primary care: one year results - Xavier HUMBERT (Caen)
 - PM1-052 - Drug safety and big clinical data: detection of drug-induced anaphylactic shocks (BREIZH project) - Marie-Noëlle OSMONT (Rennes)
 - PM1-053 - Reconciliation of adverse events databases: a critical point in clinical trial results - Mathieu LEFEBVRE (Lyon)
 - PM1-054 - HOPIPRAC, PRAC signals validation sentinel system, from a hospital data warehouse. - Layal EL ARIDI (Brest)
 - PM1-055 - VigiBIP®, the first Mobile App for PharmacoVigilance and AddictoVigilance: a balance sheet after a 2 years' use - François MONTASTRUC (Toulouse)
 - PM1-056 - A pilot study of the Vigi4MED project: comparison of adverse drug reactions (ADRs) of duloxetine between patients' forum posts and the French pharmacovigilance database (FPVD) – Florelle BELLET (Saint-Etienne)

Zone violette

- Modérateurs: Emmanuel OGER (Rennes)
Marie-Christine PERAULT-POCHAT (Poitiers)
- PM1-057 - Patient's falls during hospitalization: impact of newly prescribed fall risk-increasing drugs - Thomas GAILLAND (Grenoble)
 - PM1-058 - Crushing drugs in Geriatric units: impact of cleaning methods - Gwladys BOURDENET (Rouen)
 - PM1-059 - Exposure to drugs of abuse must be taken into account for evaluation of adverse drug reactions: evidence from serotonin syndrome related to opioid medicines in the WHO pharmacovigilance database Vigibase® - Thi Thu Ha NGUYEN (Toulouse)
 - PM1-060 - Adverse Drug Events as a cause of admission to an emergency department - Pierre PARREIN (Rouen)
 - PM1-061 - High anion gap metabolic acidosis with 5-oxoprolinuria following acetaminophen exposure : a case report - Christophe MAUCORPS (Caen)
 - PM1-062 - Risk of trauma-related hospitalisation and use of H1 antihistamines or anticholinergic drugs – Antoine PARIENTE (Bordeaux)
 - PM1-063 - Severe hyponatremia in an Emergency Department in 2015 : a retrospective observational study - Paul CLAVERIE (Limoges)
 - PM1-064 - The drugs that mostly frequently induce acute kidney injury: a case-non-case study of pharmacovigilance database - Marion PIERSON-MARCHANDISE (Amiens)

MERCREDI 19 AVRIL

16h30 - 18h00 *Amphi 210A*
Pharmacologie Cardiovasculaire



Session co-organisée avec le Groupe de Réflexion sur la Recherche Cardiovasculaire

▪ Modérateurs : Jean-Luc CRACOWSKI (Grenoble), Stéphane GERMAIN (Paris)

[Conférence invitée](#)

16h30 Cardioprotection : y a-t-il un renouveau possible ? - Alain BERDEAUX (Créteil)

[Communications libres](#)

- 17h00 CO-019 - Efficacy and harm of Minoxidil in children with Williams Beuren Syndrome: results of a double blind randomized controlled trial - Guillaume GRENET (Lyon)
- 17h10 C020 - Effectiveness of combinations of drugs recommended for secondary prevention after acute coronary syndrome - Julien BEZIN (Bordeaux)
- 17h20 C021 - DOACs prescriptions: are guidelines respected? - Marjorie BERNIER-LAHAIE (Nice)
- 17h30 C022 - Improved metabolic syndrome-related right and left ventricular dysfunction by the dual ETA-ETB receptor antagonist macitentan - Marianne LACHAUX (Rouen)
- 17h40 C023 - Prevention of mitochondrial permeability transition pore opening by novel CyPD inhibitors in cardiac mitochondria - Mathieu PANEL (Créteil)
- 17h50 C024 - Comparative safety of drugs targeting the NO-sGC-cGMP pathway in pulmonary hypertension: a meta-analysis and a disproportionality analysis from Vigibase® - Charles KHOURI (Grenoble)

16h30 - 18h00 *Amphi 210B*

Actualités sur le médicament et actualités thérapeutiques :
ce qui a changé ma pratique ?

▪ Modérateurs : Maurice LAVILLE (Lyon), Patrick MISMETTI (Saint-Etienne)

[Conférences invitées](#)

- 16h30 Prophylaxie pré-exposition : les antirétroviraux chez les personnes séronégatives à haut risque de contamination par le VIH - Jade GHOSN (Paris)
- 16h45 Les nouvelles biothérapies dans le psoriasis, le rhumatisme psoriasique et la spondylarthrite - Philippe BERTIN (Limoges) et Emilie SBIDIAN (Créteil)
- 17h00 Le Tocilizumab dans la maladie de Horton - Philippe BERTIN (Limoges)
- 17h15 La nouvelle classification des psychotropes - Célia LLORET LINARES et le Groupe de Neuropsychopharmacologie de la SFPT (Paris)
- 17h30 Les inhibiteurs de PCSK9 : une révolution post-statine ? - Vincent DURLACH (Reims)
- 17h45 L'utilisation du Ferinject dans l'insuffisance cardiaque - Eric ROUPIE (Caen)

MERCREDI 19 AVRIL

16h30 - 18h00 *Amphi 110*
Neuro-Psycho-Pharmacologie

- Modérateurs : Dominique MARTIN (ANSM), Luc ZIMMER (Lyon)

Conférence invitée

16h30 Acide valproïque et plasticité cérébrale : le meilleur et le pire - Régis BORDET (Lille)

Communications libres

- 17h00 CO-025 - The COMT Val(108/158)Met genetic polymorphism and response to venlafaxine in patients with major depression - Adela TARANU (Le Kremlin Bicêtre)
- 17h10 C026 - Risk of heart failure with Dopamine Agonists in Patients with Parkinson’s disease: differences between ergot and non-ergot derivatives - François MONTASTRUC (Toulouse)
- 17h20 C027 - TNF-α Inhibitors and Psychotic Side Effects: Results from the French Pharmacovigilance Database - Cécile YELNIK (Lille)
- 17h30 C028 - A simultaneous PET-MRI study for the exploration of the pharmacological concept of 5-HT1A receptor biased agonists - Benjamin VIDAL (Lyon)
- 17h40 C029 - Identifying drug induced neuropathies in a hospital database: clinical data warehouse (CDW) versus Medicalized Information System Program (PMSI) - Research included in BREIZH project - Hélène JANTZEM (Brest)
- 17h50 C030 - Triptan use and serious cardiovascular events in elderly over 65 years in France : a nationwide retrospective propensity-matched cohort study - Joëlle MICALLEF (Marseille)

18h00 - 19h30 *Amphi 210A*
Réunion CNPM

18h00 - 19h30 *Amphi 210B*
Réunion AEPFP

18h00 - 19h30 *Amphi 110*
Réunion APNET

JEUDI 20 AVRIL

08h30 - 10h00 *Amphi 500*
Diabète

Session co-organisée avec la Société Francophone de Diabète



- Modérateurs : Jean DOUCET (Rouen), André SCHEEN (Liège - Belgique)

Conférences invitées

- 08h30 Quelles cibles et quels objectifs ? - Stéphane DALLE (Montpellier)
- 09h00 Antidiabétiques : au-delà du glucose - André SCHEEN (Liège)
- 09h30 Quelle méthodologie pour l’évaluation des anti-diabétiques ? - François GUEYFFIER (Lyon)

10h00 – 10h30
Pause café et visite des stands

10h30 – 11h30 *Amphi 500*
Diabète



Session co-organisée avec la Société Francophone de Diabète

- Modérateurs : Jean DOUCET (Rouen), André SCHEEN (Liège - Belgique)

Conférences invitées

- 10h30 Antidiabétiques et risque médicamenteux - Jean-Luc FAILLIE (Montpellier)
- 11h00 Les antidiabétiques dans la vraie vie : quelle personnalisation? - Ronan ROUSSEL (Paris)

11h30 - 12h30 *Amphi 500*
Table ronde : Quelle responsabilité juridique et éthique pour les professionnels du médicament ?

- Modérateurs : Véronique LAMARQUE-GARNIER (Paris), Mathieu MOLIMARD (Bordeaux)

Conférences invitées

- 11h30 Clémentine LEQUILLERIER (Paris)
- 11h50 Blandine FAURAN (Paris)
- 12h10 Table ronde - Dominique DEPLANQUE (Lille), Claire LE JEUNNE (Paris), Marie-Christine PERAULT-POCHAT (Poitiers), Pascal BOUSQUET (Strasbourg), Eric BASEILHAC (Leem)

JEUDI 20 AVRIL

13h00 – 14h00 *Amphi 500*

Sujets d’actualité

- Modérateurs : Pascale JOLLIET (Nantes), Faiez ZANNAD (Nancy)

13h00 Actualités sur le règlement essais cliniques et la loi Jardé - François LEMAIRE (Créteil)

- Modérateurs : Régis BORDET (Lille), Marie-Christine PERAULT-POCHAT (Poitiers)

13h30 Les défis de la Pharmaco-Surveillance : quelles réponses pour demain - Dominique MARTIN (ANSM), Annie-Pierre BERA-JONVILLE (Tours), Joëlle MICALLEFF (Marseille)

14h00 - 15h00 *Amphi 210A*

Actualités sur le médicament

- Modérateurs : Claire LE JEUNNE (Paris), Agnès SOMMET (Toulouse)

Conférences invitées

Controverse : Généralisation des médicaments contre l’hépatite C : quel choix pour quel objectif ?

14h00 Patrick HILLON (Dijon)

14h30 Jean-François BERGMANN (Paris)

14h00 - 15h00 *Amphi 210B*

Communications libres et Prix de thèse

- Jury : Laurence DAULHAC (Clermont Ferrand), Julie DEGUIL (Lille), Milou DRICI (Nice), Pascale JOLLIET (Nantes), Pierre MARQUET (Limoges)

- Modérateurs : Milou DRICI (Nice), Pierre MARQUET (Limoges)

Prix de thèse

14h00 CO-031 - Impact of different contraceptive pills on the potentiation of drug-induced QT interval prolongation - Joe-Elie SALEM (Paris)

14h10 CO-033 - An original pharmacoepidemiological– pharmacodynamic method: application to antipsychotic-induced movement disorders - François MONTASTRUC (Toulouse)

14h20 CO-034 - A sensitive LC-MS/MS method for the quantification of regioisomers of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids in human plasma during endothelial stimulation - Thomas DUFLOT (Rouen)

Communications libres

14h30 CO-035 - Assessment of clinical practice: drug’s prescriptions in hospitalized patients aged 75 years and older - Lisa MONDET (Amiens)

14h40 CO-036 - Proton Pump Inhibitors: real indication or trivialized prescription? - Jeanne THOREL (Toulouse)

15h00 – 16h30 *Amphi 500*

Assemblée Générale de la SFPT

16h30 - 18h00 *Amphi 210A*

Traitements pro et anti-angiogéniques

- Modérateurs : Pascal BILBAULT (Paris), Vincent RICHARD (Rouen)

Conférences invitées

16h30 Actualités sur les traitements anti-angiogéniques - Eric RAYMOND (Lausanne)

17h00 Les effets indésirables des anti-VEGF, focus sur les effets cardio-vasculaires - Emmanuelle BONDON-GUITTON (Toulouse)

17h30 Biothérapies pro-angiogéniques dans les maladies cardiovasculaires - Ebba BRAKENHIELM (Rouen)

16h30 - 18h00 *Amphi 210B*

STP – Personnalisation des traitements

- Modérateurs : Chantal BARIN LE GUELLEC (Tours), Céline VERSTUYFT (Le Kremlin Bicêtre)

Conférence invitée

16h30 L'épigénétique peut-elle nous aider à prédire la réponse aux traitements des maladies autoimmunes et inflammatoires chroniques ? - Corinne MICELLI (Paris)

Communications libres

17h00 CO-037 - Towards therapeutic drug monitoring of everolimus? Results of an exploratory study of the dose-exposure relationships - Marine DEPPENWEILER (Limoges)

17h10 CO-038 - Tacrolimus intracellular concentrations for the longitudinal follow up of liver transplant recipients: Yes we CaN ! - Camille TRON (Rennes)

17h20 CO-039 - Therapeutic drug monitoring of Beta-Lactams administrated in continuous infusion in intensive care unit - Dounia SATORI (Marseille)

17h30 CO-040 - Population pharmacokinetics of tacrolimus early after liver transplantation: why therapeutic drug monitoring is mandatory - Antoine PETITCOLLIN (Rennes)

17h40 CO-041 - Cypascan: a software dedicated to cytochrome P450 allele calling using the star nomenclature from Next-Generation Sequencing (NGS) data - Claire-Cécile BARROT (Limoges)

17h50 CO-042 - Posaconazole tablets versus posaconazole oral suspension in lung transplant patients: which consequences on immunosuppressive therapy? - Elodie GAUTIER-VEYRET (Grenoble)

18h00 – 19h30 *Amphi 500*

Conférence Grand Public

- Modérateur : Vincent RICHARD (Rouen)

18h00 Se réconcilier avec le médicament - Jean-François BERGMANN (Paris)

JEUDI 20 AVRIL

18h00 - 19h30 Happy Hour Posters *RDC*

Zone jaune

- Modérateurs : Eric DAILLY (Nantes)
Françoise STANKE-LABESQUE (Grenoble)
- PM2-001 - Are Prophylactic and Therapeutic Target Concentrations Different? The Case of Lopinavir/ritonavir or Lamivudine Administered to Infants for the Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding - Frantz FOISSAC (Paris)
 - PM2-002 - Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or + daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study) - Claire LAFOREST (Rennes)
 - PM2-003 - Population Pharmacokinetic Modeling of Tenofovir in the Male Genital Tract of HIV-infected Patients – Déborah HIRT (Paris)
 - PM2-004 - Comparison of adherence to antiretroviral therapy (ART) generic versus brand ART substitutable by generics (currently available in France) by breaking or not fixed-dose combinations (FDC) in HIV-infected patients: a cohort study from the French National Healthcare Insurance Database (SNIIRAM) in Midi-Pyrénées region – Agnès SOMMET (Toulouse)
 - PM2-005 - Exposure to sofosbuvir and daclatasvir is unchanged in liver transplant patients on cyclosporine or tacrolimus based immunosuppression - Lauriane GOLDWIRT (Paris)
 - PM2-006 - Dolutegravir withdrawal and Adverse Drug Reactions: A retrospective study in Midi-Pyrénées – Haleh BAGHERI (Toulouse)
 - PM2-007 - Monitoring of adherence to calcineurin inhibitors using their longitudinal exposures in kidney transplant patients - Danko STAMENIC (Limoges)
 - PM2-008 - Relationship between exposure to calcineurin inhibitors over the first year after kidney transplantation and infections: a cohort study – Caroline MONCHAUD (Limoges)

Zone orange

- Modérateurs : Nicolas AUTHIER (Clermont-Ferrand)
Maryse LAPEYRE-MAESTRE (Toulouse)
- PM2-009 - Patterns of use and diversion of benzodiazepines and related substances in France : results of the OSIAP survey – Maryse LAPEYRE-MESTRE (Toulouse)
 - PM2-010 - What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review - Emilie JOUANJUS (Toulouse)
 - PM2-011 - Treatment of colchicine overdose with colchicine-specific Fab fragments: a pre-clinical study in Göttingen mini-pigs - Nicolas FABRESSE (Montigny-Le-Bretonneux)
 - PM2-012 - Pharmacists and request for drugs by minors: current situation in the Pays-de-La-Loire area - Marylène GUERLAIS (Nantes)
 - PM2-013 - Use of multiple sources and capture-recapture method to estimate the number of patients treated with baclofen for alcoholdependence in 2013 in a French region. - Marine AUFFRET (Lille)
 - PM2-014 - Sexual dysfunctions induced by off label use of baclofen for alcoholdependance induced: report of 14 cases – Marine AUFFRET (Lille)
 - PM2-016 - Cannabis hyperemesis: a new clinical entity ? - Nicolas WAGNER (Nantes)
 - PM1-034 - Recreational use of dextromethorphan: data from the French Toxicovigilance and Poison Control Centers - Valérie GIBAJA (Nancy)

Zone rose

- Modérateurs : Youssef BENNIS (Amiens)
Christian FUNCK-BRENTANO (Paris)
- PM2-017 - Musculoskeletal adverse effects associated with rivaroxaban: Analysis from the French Pharmacovigilance database - Pascale LAINÉ-CESSAC (Angers)
 - PM2-018 - Pharmacological Prevention of Sudden Death in Adults – François GUEYFFIER (Lyon)
 - PM2-019 - Population Pharmacokinetic and Pharmacodynamic model of Unfractionated Heparin during cardiac surgery - Xavier DELAVENNE (Saint-Etienne)
 - PM2-020 - Power assessment of rivaroxaban pharmacogenomics by simulation study - Clément BOLDIN (Saint-Etienne)
 - PM2-021 - Initiation of Fluindione : predictive factors of equilibration - Charlotte MARCHAND (Rouen)
 - PM2-022 - Intra-cranial haemorrhage and antithrombotics : therapeutic follow-up - Marwa KLAI (Saint-Etienne)
 - PM2-023 - Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonist – Theodora BEJAN-ANGOULVANT (Tours)
 - PM2-024 - Adverse Drug Reactions related to Direct Oral Anticoagulant : patient’s internet narratives versus pharmacovigilance database – Haleh BAGHERI (Toulouse)

Zone rouge

- Modérateurs : Zoubir DJERADA (Reims)
David TERNANT (Tours)
- PM2-025 - New posaconazole formulation : which impact on therapeutic drug monitoring in hematological patients ? - Julia TONINI (Grenoble)
 - PM2-026 - Correlation between received and calculated dose of vancomycin in renal failure patients - Issam SALOUAGE (Tunis - Tunisie)
 - PM2-027 - Tacrolimus overexposure in kidney transplant recipients during the first post-operative week: is there an impact on kidney function? - Florian LEMAITRE (Rennes)
 - PM2-028 - Measuring tacrolimus concentration in bile from liver transplant recipient: an alternative matrix for therapeutic drug monitoring and pharmacokinetic studies? - Camille TRON (Rennes)
 - PM2-029 - Development of a population model and a bayesian estimator for Envarsus® in liver transplantation - Jean-Baptiste WOILLARD (Limoges)
 - PM2-030 - Inosine 5’-MonoPhosphate Dehydrogenase (IMPDH) phenotype in adults and children with or without azathioprine therapy - Antony CITTERIO-QUENTIN (Lyon)
 - PM2-031 - High-dose methotrexate population pharmacokinetic and pharmacogenetic analysis in pediatric patients with osteosarcoma – Naïm BOUAZZA (Paris)

Zone bleue

Modérateurs : Chantal BARIN LE GUELLEC (Tours)
Sébastien FAURE (Angers)

- PM2-032 - Population pharmacokinetics of infliximab and quantification of the risk of immunization towards infliximab in children with Crohn's disease - Antoine PETITCOLLIN (Rennes)
- PM2-033 - Eliglustat and CYP2D6 genotyping prior to initiation of therapy : Frequencies of CYP2D6 phenotype across French patients with type 1 Gaucher disease - Céline VERSTUYFT (Le Kremlin-Bicêtre)
- PM2-034 - Detection of BRAFV600 mutation in circulating cell free DNA, a helpful tool for a better therapeutic monitoring - Baptiste LOUVEAU (Paris)
- PM2-035 - How to diagnose early 5-azacytidine induced pneumonitis, a case report - Laurence GABRIEL (Troyes)
- PM2-036 - High-dose methotrexate and risk factors for intoxication - Béatrice CLARIVET (Montpellier)
- PM2-037 - Descriptive pharmacokinetic characteristics of a “real life” small cohort of BRAFV600E mutated metastatic melanoma patients treated with dabrafenib as monotherapy - Baptiste LOUVEAU (Paris)
- PM2-038 - NSAIDs and oxycodone-induced Liver injury associated to CYP2C9 and GST mutations: a case report - Dorra AMOR (Le Kremlin Bicêtre)
- PM2-039 - TDM of Regorafenib in patients with metastatic colorectal cancer: preliminary results – Anne HULIN (Créteil)

Zone verte

Modérateurs : Cyril GOUDET (Montpellier)
Joëlle MICALLEF (Marseille)

- PM2-040 - Pharmacokinetic-pharmacodynamic modeling of levodopa and metabolites in Parkinson's disease patients - Amélie MARSOT (Marseille)
- PM2-041 - Safety and efficacy of Dimethylfumarate in relapsing remitting multiple sclerosis: a real life regional study - Matthieu BÉREAU (Besançon)
- PM2-042 - Phenotypic assessment of drug metabolic pathways and P-glycoprotein in patients treated with antidepressant - Celia LLORET-LINARES (Paris)
- PM2-043 - Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: High Prevalence of Functional Abnormalities of Cytochrome P450 2D6. Preliminary data and ongoing study protocol - Susanne THÜMMLER (Nice)
- PM2-044 - Cyamemazine (Tercian®): Exploration of extrapyramidal syndrome cases contained in the French pharmacovigilance database - Charles KHOURI (Grenoble)
- PM2-045 - Atropinic (anticholinergic) burden in antipsychotic-treated patients: a cross-sectional study in a French Pharmacovigilance Database – François MONTASTRUC (Toulouse)
- PM2-046 - A comparison of morphine and metabolites plasma levels following sustained release formulation of morphine administration in Roux-en-Y gastric bypass subjects versus matched nonsurgical control subjects: The OBEMO 2 study - Lorry HACHON (Paris)
- PM2-047 - What are uronephrologic complications related to the consumption of psychoactive substances? - Michel SPADARI (Marseille)

Zone beige

Modérateurs : Jean-Luc FAILLIE (Montpellier)
Marie-Laure LAROCHE (Limoges)

- PM2-048 - Analysis of drug interactions involved in serious adverse effects in the French National Pharmacovigilance database: Focus on death outcomes and their avoidabilities - Mélanie MOLTENIS (Besançon)
- PM2-049 - Adequacy of oral information given to research participants as regards the declaration of Helsinki - Adeline PARIS (Grenoble)
- PM2-050 - Drug identification and risk of confounding look-alike medicines ; perception of patients, physicians and pharmacists - Frédéric TRANCHARD (Toulouse)
- PM2-051 - Identifying potential drug-drug interactions in the French health insurance databases: application in multiple myeloma patients - Aurore PALMARO (Toulouse)
- PM2-052 - Development and validity of a checklist assessing the risk of bias of randomized trials, observational studies and systematic reviews analyzing drug adverse events - Jean-Luc FAILLIE (Montpellier)
- PM2-053 - Knowledge of drug-drug interactions by general practitioners residents: a prospective cohort study - Marie SOULIE (Paris)
- PM2-054 - Getting vaccinated or not? : a survey on hospital staff motivations to receive influenza vaccine – Geneviève DURRIEU (Toulouse)
- PM2-055 - Data and Safety Monitoring Board activity in establishments of Inter-Regional Group for Clinical Research and Innovation of South Western France and overseas departments: 5-years activity report - Sophie DURANTON (Poitiers)

Zone violette

Modérateurs : Antoine COQUEREL (Caen)
Mathieu MOLIMARD (Bordeaux)

- PM2-056 - Microparticles: Impact on the safety profile of active substances? - Romuald SOICHEZ (Besançon)
- PM2-057 - Bilateral acute iris transillumination : a new serious ocular adverse effect of moxifloxacin - Roxane GOULAM (Paris)
- PM2-058 - Toctino® (alitretinoin) : A French follow-up study of Pharmacovigilance – Annie-Pierre JONVILLE-BERA (Tours)
- PM2-059 - Bisphosphonate-related osteonecrosis of the jaw: descriptive analysis from the French national pharmacovigilance database - Paul DE BOISSIEU (Reims)
- PM2-060 - Drug-induced dental caries in VigiBase: bisphosphonate, adrenergic, immunosuppressant and hyperglycemic drugs - Emilie PATRAS DE CAMPAIGNO (Toulouse)
- PM2-061 - Aseptic osteonecrosis after non-systemic administration of corticosteroids: french pharmacovigilance database and literature analysis - Nicolas SERANDOUR (Nantes)
- PM2-062 - Pustulosis of the folds induced by tumor necrosis factor-α inhibitors: a new dermatologic entity? - Charlotte RAIMBAULT (Angers)
- PM2-063 - Post-marketing surveillance of ROACTEMRA® (tocilizumab) safety: a six-year follow-up in France - Chouki CHENAF (Clermont-Ferrand)

JEUDI 20 AVRIL

10h00 – 16h00 *Amphi 110*
Journée des CIC

09h00 – 10h00 Accueil café - Ouverture, Hélène ESPEROU

10h00 – 10h45 **Conférence : Recherche translationnelle inversée**
Comment les CIC incitent à la recherche fondamentale ? – Faiez ZANNAD (CIC Nancy)

▪ Président de séance : Faiez ZANNAD

10h45 – 11h05 **La bibliométrie des CIC**
La bibliométrie à l'Inserm : une aide à l'évaluation et un outil de stratégie
Elisabeth ADJADJ (DESP – Inserm, Paris)

11h05 – 12h00 **Big data, open data, data sharing**
Aspects réglementaires, Frédérique LE SAULNIER (ISP Inserm, Paris)
Infrastructure SNDS, Grégoire REY (CépiDc-Inserm, Paris)
Big data & Enjeux en recherche clinique, Alexandre MOREAU-GAUDRY (CIC de Grenoble)

12h00 – 13h30 **Pause déjeuner**

▪ Président de séance : Dominique DEPLANQUE

13h30 – 14h10 **Réglementaire et éthique**
Evolution de la réglementation européenne sur les dispositifs médicaux
Marlène DURAND (CIC de Bordeaux)
Recherche clinique dans des populations particulières : quand l'éthique se heurte à la morale -
Marc BARDOU (CIC de Dijon)

14h10 – 15h10 **Présentation de projets**
NeoDoloris : Développement d'un dispositif d'évaluation de la douleur du nouveau-né -
Julien DE JONCKEERE (CIC de Lille)
Occlusion veineuse rétinienne - Michel PAQUES (CIC 15/20, Paris)
Epipage 2 - Pierre-Yves ANCEL (CIC de Paris Centre)
Diabète de type 2 et complications rénales : du biomarqueur à l'essai d'intervention –
Samy HADJADJ (CIC de Poitiers)

15h10 – 16h00 **Vie des CIC**
Retour de l'enquête sur les doctorants dans les CIC - Bruno LAVIOLLE (CIC de Rennes)

16h00 **Clôture**

VENDREDI 21 AVRIL

08h00 - 09h00 *Amphi 110*
Réunion REVISE

09h00 - 10h30 *Amphi 210A*
Sclérose en Plaques
▪ Modérateurs : Gilles PAINAUD (Tours), Fanny ROCHER (Nice)
[Conférences invitées](#)

09h00 De la physiopathologie à la pharmacologie - Lennart MARS (Lille)
09h30 Événements démyélinisants et biothérapies (non neurologiques) - Gilles DEFER (Caen)
10h00 Conduire un traitement médicamenteux de la sclérose en plaques : quels critères pour le meilleur rapport bénéfice/risques - Thibault MOREAU (Dijon)

09h00 - 10h30 *Amphi 210B*
Pharmaco-Surveillance
▪ Modératrices : Joëlle MICALLEF (Marseille), Caroline VICTORRI-VIGNEAU (Nantes)
[Conférence invitée](#)

09h00 Fentanylloïdes : la vigilance des ultra opioïdes - Michel MALLARET (Grenoble)
[Communications libres](#)

09h30 CO-043 - Overview of new doping trends by misuse of patented drugs, biosimilars or new agents in development. Consequences for the fight against doping - Antoine COQUEREL (Caen)
09h40 CO-044 - Recreational antitussive and antihistamine drug poisoning in adolescents and young adults reported to a French Poison Control Center - Nicolas DELCOURT (Toulouse)
09h50 CO-045 - Safety of cabergoline in lactation inhibition during the puerperal period - Laurent CHOUCHANA (Paris)
10h00 CO-046 - Abuse and dependence potential of levetiracetam - Basile CHRETIEN (Caen)
10h10 CO-047 - Contribution of social media content monitoring to the identification of suspected adverse reactions to birth control arm implants: a comparison with literature monitoring - Yannick LE PRIOL (Paris)
10h20 CO-048 - Use of digestive disorders medications by children exposed in utero to atropinic drugs - Justine BENEVENT (Toulouse)

10h30 – 11h00
Pause café et visite des stands

VENDREDI 21 AVRIL

11h00 - 12h00 *Amphi 210A*
Pharmacologie clinique / méthodologie

- Modérateurs : Pierre-Olivier GIRODET (Bordeaux), Olivier BLIN (Marseille)

Communications libres

- 11h00 CO-049 - Salbutamol nebulization during non-invasive ventilation in exacerbated COPD patients: a multicentre blinded randomized controlled trial - Laetitia BODET-CONTENTIN (Tours)
- 11h10 CO-050 - Use of oral glucocorticoids in adults: a population-based study - Anne BÉNARD-LARIBIÈRE (Bordeaux)
- 11h20 CO-051 - On demand sildenafil as a treatment of Raynaud's Phenomenon: a series of N-of-1 trials - Matthieu ROUSTIT (Grenoble)
- 11h30 CO-052 - Hemorrhagic and thrombotic events in patients treated with anti-angiogenic therapies: impact of study design on the results assessed by meta-analysis - Jane-Chloé TRONE, Silvy LAPORTE (Saint-Etienne)
- 11h40 CO-053 - The key role of inhaler use in COPD: a real-life study - Mathieu MOLIMARD (Bordeaux)
- 11h50 CO-054 - Impact of activated charcoal early and delayed administration on rivaroxaban pharmacokinetic - Edouard OLLIER (Saint Etienne)

11h00 - 12h00 *Amphi 110*
Communications libres

- Modérateurs : Pierre-François DEQUIN (Tours), Elisabeth POLARD (Rennes)
- 11h00 CO-055 - Impact of Rennes incident on French clinical trial regulation - Cyrielle CONCHE (Lyon)
- 11h10 CO-056 - Exposure to troxerutin during pregnancy: risk of congenital anomalies for the fetus? - Caroline HURAUULT-DELARUE (Toulouse)
- 11h20 CO-057 - What to think about patient notifications? - Audrey LAGNEAU (Nice)
- 11h30 CO-058 - Evaluation of safety and efficacy of antiTNFα treatment during pregnancy in inflammatory bowel disease. Study on the French national PMSI database (EVASION) - Maxime LUU (Dijon)
- 11h40 CO-059 - Transgenerational effects of in utero exposure to diethylstilbestrol (DES): genital birth defects in « DES grandsons » (third generation) - Christophe FERREIRA-DE-MATOS (Toulouse)
- 11h50 CO-060 - Infliximab serum concentration and risk of infections in spondyloarthritis - Theodora BEJAN-ANGOULVANT (Tours)

11h00 - 12h00 *Amphi 210B*
STP - Personnalisation des traitements

- Modérateurs : Xavier DELAVENNE (Saint-Etienne), Jean-Baptiste WOILLARD (Limoges)

Communications libres

- 11h00 CO-061 - Population pharmacokinetic-pharmacodynamic modeling of spinal anesthesia with ropivacaine - Zoubir DJERADA (Reims)
- 11h10 CO-062 - Population kinetics of factor VIII in mild hemophilia A patients following desmopressin intravenous administration - Cyril LEVEN (Brest)
- 11h20 CO-063 - Towards therapeutic drug monitoring of mycophenolic acid in cicatricial pemphigoid patients - Jean-Baptiste WOILLARD (Limoges)
- 11h30 CO-064 - Estimating pharmacokinetic parameters of infliximab using only one concentration measurement - David TERNANT (Tours)
- 11h40 CO-065 - Population pharmacokinetics and Monte-Carlo simulations of posaconazole administered as tablets in a real-life cohort of patients with hematological malignancies: towards dose reduction? - Antoine PETITCOLLIN (Rennes)
- 11h50 CO-066 - Development of a Bayesian estimator based on limited sampling strategies for Advagraf® and Prograf® in de novo adult liver transplant patients - Camille RIFF (Limoges)

12h00 – 12h15 *Amphi 210A*
Remise des différents prix de la SFPT

Clôture du Congrès

Posters affichés Jour 1 : MERCREDI 19 AVRIL

- PS1-001 - A beneficial effect of dulaglutide - Corinne SIMON (Tours)
- PS1-002 - A comparative study of QT prolongation with Serotonin Reuptake Inhibitors (SRIs) – François MONTASTRUC (Toulouse)
- PS1-003 - Accidental ingestion of a minoxidil hair lotion in a child: a severe case report - Stéphane SAVOUROUX (Nantes)
- PS1-004 - Addiction to kaolin consumption during pregnancy: what about metropolitan France ? - Pascal CAILLET (Nantes)
- PS1-005 - Adherence to guidelines for initial treatment of hypertension : description, trends over time and determinants - Marine CAMPION (Rennes)
- PS1-006 - Adverse Drug Reactions of idélalisib: study in the French Pharmacovigilance Database - Sylvine PINEL (Paris)
- PS1-007 - Adverse effects related to brentuximab: a systematic retrospective study - Béatrice CLARIVET (Montpellier)
- PS1-008 - Albuminemia in preoperative: Interest and limit - Hakim EL ALAMA (Casablanca - Maroc)
- PS1-009 - An UPLC-MS/MS method for human plasma quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib). Application to treated melanoma patients - Marine ROUSSET (Bordeaux)
- PS1-010 - Antibiotic's real life profile and safety : a regional study - Marie-Blanche VALNET RABIER (Besançon)
- PS1-011 - Antineoplastic, which impact of age and comorbidities? – Malak ABOU TAAM (Reims)
- PS1-012 - Antiproliferative effect of Berberis hispanica alkaloids extract on Hep2 laryngeal cancer cells - Amina BOUDJLIDA (Alger - Algérie)
- PS1-013 - Antipsychotic use in pregnancy in France: Is Reproductive Safety different according to the indication? - François MONTASTRUC (Toulouse)
- PS1-014 - Anti-thrombotic effects of the polysaccharide from Cydonia oblonga Miller - Adili ABUDOUHEMAN (Urumqi - Chine)
- PS1-015 - Assessment of vancomycin trough concentration in severe infections - Mouna BEN SASSI (Tunis - Tunisie)
- PS1-016 - Atypical response of spondyloarthritis to biological treatments: think about Whipple's disease – Pierre GILLET (Vandœuvre Lès Nancy)
- PS1-017 - Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation – Theodora ANGOULVANT (Tours)
- PS1-018 - Bullous hemorrhagic dermatosis, unfractionated heparine, low-molecular-weight heparin, danaparotide and fondaparinux: analysis of the French pharmacovigilance database - Marta UCEDA-MARTIN (Strasbourg)
- PS1-019 - Coma following AB-FUBINACA and 3-MeO-PCP consumption: a case report - Hélène LOMENECH (Nantes)
- PS1-020 - Comparative P-gp and BCRP efflux transport of direct oral anticoagulants - Sophie HODIN (Saint-Etienne)
- PS1-021 - Consumption of opioid analgesics, 2006-2015 - Simon COUTURIER (Bordeaux)
- PS1-022 - Continuous infusion of vancomycin in critically ill children: do we achieve the target? - Mathieu GÉNUINI (Paris)
- PS1-023 - Coronary heart disease during tyrosine kinase inhibitors therapy used in haemato-oncology : Study in the French

Pharmacovigilance Database - Sandrine COMBRET (Dijon)

- PS1-024 - Creation of pharmacovigilance accountability study software - Hakim EL ALAMA (Casablanca - Maroc)
- PS1-025 - Dabigatran-related nephropathy in a patient with a pre-existing vascular nephropathy - Marie-Noëlle OSMONT (Rennes)
- PS1-026 - Development and validation of an HPLC method for the therapeutic drug monitoring of 11 beta-lactams antibiotics - Elise PAPE (Nancy)
- PS1-027 - Development of a new HPLC method for determination of Capecetabine and its metabolite 5FU in plasma - Dorra BEN SAID (Tunis - Tunisie)
- PS1-028 - Development of a non-parametric population model and a bayesian estimator for tacrolimus in renal Tunisian transplant patients - Mouna BEN SASSI (Tunis - Tunisie)
- PS1-029 - Development of follicular B cell lymphoma after treatment with Sofosbuvir in chronic hepatitis C virus - Roya NILI (Paris)
- PS1-030 - Direct Oral Anticoagulants appropriateness' prescriptions in 2016: analysis from community pharmacies - Johana BÉNE (Lille)
- PS1-031 - Direct Oral Anticoagulants appropriateness' prescriptions in a French University Hospital Center in 2016. – Johana BENE (Lille)
- PS1-032 - Disulone® and hyperferritinemia : a case report - Charlotte ORSINI (Rouen)
- PS1-033 - Donepezil-induced hypersexuality: an unexpected adverse drug reaction - Louise TRIQUET (Rennes)
- PS1-034 - Drug-induced blepharospasm: a review of 20 years' experience in the French pharmacovigilance database – Alexandre QUILLET (Poitiers)
- PS1-035 - Drug-induced bone loss: A study of the French and Spanish Pharmacovigilance DataBases – Haleh BAGHERI (Toulouse)
- PS1-036 - Drugs incriminated in fixed drug eruption - Mouna BEN SASSI (Tunis - Tunisie)
- PS1-037 - Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4 - Charleine ZUSSY (Montpellier)
- PS1-038 - Effect of glucarpidase on methotrexate levels and renal function : about five cases - Aurélie MARTINEZ (Montpellier)
- PS1-039 - Effect of Total Flavonoids of Cydonia oblonga Mill. on blood pressure, myocardial hypertrophy and mediators of inflammation in spontaneously hypertensive rats - Ainiwaer WUMAIER (Urumqi - Chine)
- PS1-040 - Effect of total flavonoids of Cydonia oblonga Miller on the blood pressure and vascular endothelial function in spontaneously hypertensive rats – Wumaier AINIWAER (Urumqi - Chine)
- PS1-041 - Efficacy of metformin monotherapy on glycemic control, weight and serum lipids in drug-naïve patients with type 2 diabetes: systematic review and meta-analysis of randomized placebo-controlled trial – Jean-Luc FAILLIE (Montpellier)
- PS1-042 - Encapsulated exenatide once weekly: is there a link between the occurrence of cutaneous nodules and a decrease in efficacy? - Perrine ROBIN (Montpellier)
- PS1-043 - Energy drinks are not "so good"... - Caroline VIGIER (Nice)
- PS1-044 - Evaluation of medication adherence in elderly patients hospitalized in the endocrinology/diabetology service of the Tunisian military hospital - Safa LOUHICHI (Tunis - Tunisie)

Posters affichés Jour 2 : JEUDI 20 AVRIL

- PS1-045 - Evaluation of placebo use by Haitian physicians in 2016 - Elysée Junior Nérissou JOSEPH (Port-Au-Prince - Haïti)
- PS1-046 - Evaluation of the knowledge of the treatment of chronic disease in a cohort of elderly subjects - Lobna BEN MAHMOUD (Sfax - Tunisie)
- PS1-047 - Evaluation of the nocebo effect: descriptive study in a French pharmacy – Marion LEPELLEY (Grenoble)
- PS1-048 - Exceptional case of hepatotoxicity associated with methoxsalen - Fatma BEN SALEM (Tunis - Tunisie)
- PS1-049 - First case of tubulointerstitial nephropathy associated with vedolizumab - Frédérique BEAU-SALINAS (Tours)
- PS1-050 - Haematological side effects of drugs used in psychiatry – Anne DAUTRICHE (Dijon)
- PS1-051 - High doses of biotin in chronic progressive multiple sclerosis, patient's appreciation of an effective treatment? - Laurence GABRIEL (Troyes)
- PS1-052 - IgE-mediated anaphylaxis to PPIs–cross-reacting study – Julien MAHE (Nantes)
- PS1-053 - Impairment of calcium homeostasis by methylglyoxal in cardiomyocytes via calcium channels: a key role in the development of diabetic cardiomyopathy - Hélène PEYRET (Reims)
- PS1-054 - Incidence of prescribing errors from ambulatory prescriptions in Bouaké - Mamadou KAMAGATÉ (Bouaké - Côte d'ivoire)
- PS1-055 - Increased reporting of adverse drug reactions in a hospital emergency department – Emilie DEHOURS (Toulouse)
- PS1-056 - Infections associated with ruxolitinib: study in the French Pharmacovigilance Database - Sylvine PINEL (Paris)
- PS1-057 - Influence of diet on hepatic metabolism of drugs - Oussama HADEQ (Casablanca - Maroc)
- PS1-058 - Injectable Potassium Chloride: Improve prescription to prevent accidents - Marwa KLAI (Lyon)
- PS1-059 - Interaction between statins and fusidic acid: an analysis from literature and Vigibase® data – Hélène THEOPHILE (Bordeaux)
- PS1-060 - Interest of nitrous oxide as an analgesic in dental care - Tony PRUD'HOMME (Nantes)
- PS1-061 - Interferon β -1b-induced acute pancreatitis - Imen HAMZA (Tunis - Tunisie)
- PS1-062 - Intracranial hemorrhage following oral anticoagulant treatment: a retrospective comparative study assessing short-term mortality - Marie-Delphine GUILLEMIN (Lyon)
- PS1-063 - Is psychostimulant substances use in slam a pharmacological issue ? - Benoît SCHRECK (Nantes)
- PS1-064 - Knowledge and recommendations of the population on street drugs - Mamadou KAMAGATÉ (Bouaké - Côte d'ivoire)
- PS1-065 - Kratom (*Mitragyna speciosa*) "phyto-toxicomania" : About a case of acute hepatitis – Reynald LE BOISSELIER (Caen)

- PS2-001 - Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients - Aurélie DAUMAS (Marseille)
- PS2-002 - Male infertility and drug exposure: a feasibility study using the new database HOMERE - Mélanie ARAUJO (Toulouse)
- PS2-003 - Medication adherence to antihypertensive treatment using Morisky medication adherence scale - Fatma Zahra BEN JEMIA (Tunis - Tunisie)
- PS2-004 - Medication management in the Elderly: a French cross-sectional study in Hautes-Pyrénées - Haleh BAGHERI (Toulouse)
- PS2-005 - Mepolizumab versus omalizumab and prednisone : what about the safety ? - Malak ABOU TAAM (Reims)
- PS2-006 - Methylnaltrexone (Relistor®) as a sentinel drug? Using hospital prescription to detect severe opiate-induced constipation cases and their characteristics - Farid KHELOUFI (Marseille)
- PS2-007 - Milnacipran, modulation of pain and patients with fibromyalgia - Nicolas MACIAN (Clermont-Ferrand)
- PS2-008 - Monoclonal antibodies side effects: a retrospective study of 43 patients - Fatma BEN SALEM (Tunis - Tunisie)
- PS2-009 - Myocarditis Related to ioxitalamic acid: a case report - Lobna BEN MAHMOUD (Sfax - Tunisie)
- PS2-010 - Neonatal necrotizing enterocolitis: what is the role of drugs? - Floriane TIXIER (Lyon)
- PS2-011 - Non-linear elimination pharmacokinetics of tramadol following administration of extended-release tablets - Yoann CAZAUBON (Reims)
- PS2-012 - Nonsteroidal anti-inflammatory drugs (NSAIDs) and necrotizing fasciitis: even when used by local route - Christelle PHILIBERT (Montpellier)
- PS2-013 - Ocular toxicity after intracameral injection of cefuroxime during cataract surgery : a study about French cases and a literature review - Agnès ANDORRA (Clermont-Ferrand)
- PS2-014 - Off label use of clonidine in children and adolescents: safety data from French Pharmacovigilance Database - Elodie MATUSIK (Lille)
- PS2-015 - Off-label use of clonidine in children and adolescent for attention-deficit/hyperactivity disorder in French: a study among pediatric neurologists and child and adolescent psychiatrists using the French pharmacovigilance network - Marine AUFFRET (Lille)
- PS2-016 - Olanzapine-induced stuttering: a case report and review of the literature - Frédérique BEAU-SALINAS (Tours)
- PS2-017 - Oral dosage form administration practice in children under 6 years of age: A survey study of paediatric nurses – Audrey LAJOINIE (Lyon)
- PS2-018 - Outpatient antibiotic prescriptions with high risk of bacterial resistance in France: A National Healthcare Insurance database analysis – Agnès SOMMET (Toulouse)
- PS2-019 - Outpatient consumption of antibiotics at high bacterial resistance risk in 2014 in France - Agnès SOMMET (Toulouse)
- PS2-020 - Overview of the use of a non-activated prothrombin complex concentrate as a reversal agent of direct oral anticoagulants in a hospital - Hao-Sian LY (Boulogne-Billancourt)

- PS2-021 - Paroxetine-clarithromycin: a drug-drug interaction to highlight! - Seda BAKIRCI (Nice)
- PS2-022 - Peripheral neuropathy associated with donepezil: a case report - Sabrina PIERRE (Lyon)
- PS2-023 - Pharmacovigilance National Survey of tramadol-induced Adverse Drug Reactions in adults - Florence MOULIS (Toulouse)
- PS2-024 - Population Pharmacokinetic of bupivacaine after Transversus Abdominis Plane Block after cesarean section - Hanene ELJEBARI (Tunis - Tunisie)
- PS2-025 - Population pharmacokinetics of ciprofloxacin in adult patients - Olivier MANGIN (Paris)
- PS2-026 - Posterior-Reversible Encephalopathy Syndrome (PRES) after dobutamine and atropine stress echocardiography: first case report - Camille FLECK (Dijon)
- PS2-027 - Predictors of methotrexate-induced toxicity and treatment outcome in patients with acute lymphoblastic leukemia treated with EORTC 58951 protocol - Lobna BEN MAHMOUD (Sfax - Tunisie)
- PS2-028 - Pregnancy outcome in women exposed to thiocolchicoside during pregnancy: analysis of the Terappel DataBase - Aude LAMBERT (Strasbourg)
- PS2-029 - Prescription of antidepressant drugs during pregnancy in France: a drug utilization study in EFEMERIS database - Caroline HURAUULT-DELARUE (Toulouse)
- PS2-030 - Prevalence of analgesic use in France, 2006-2014 - Amélie DAVELUY (Bordeaux)
- PS2-031 - Proactive Pharmacovigilance: description and analysis of nivolumab's safety informations identified through the clinical data warehouse (CDW) of Brest University Hospital - Hélène JANTZEM (Brest)
- PS2-032 - Proton pump inhibitors (PPI) and vitamin K antagonists (VKA) resistance: about an unknown interaction? - Louise GABORIAU (Lille)
- PS2-033 - Psychiatric adverse events during aripiprazole associated to other antipsychotics : A retrospective study of cases reported within the French Pharmacovigilance database - Farid KHELOUFI (Marseille)
- PS2-034 - Rabies vaccine-induced adverse drug reactions (ADRs): review of the French pharmacovigilance database (FPVD) between 2010 and 2015 - Colombe CALAS (Saint-Etienne)
- PS2-035 - Reconstitution error of Infanrix Hexa® vaccine: highlight of the packing modalities - Anne Lise RUELLAN (Nantes)
- PS2-036 - Redaction of a clinical trial protocol: a pragmatic check-list of safety aspects to consider - Stéphanie DURET (Bordeaux)
- PS2-037 - Reversible cerebral vasoconstriction syndrome: illicit drugs may be involved - Marie GÉRARDIN (Nantes)
- PS2-038 - Risk of "targeted therapies" in the elderly: the example of protein kinase inhibitors - Pascale OLIVIER (Toulouse)
- PS2-039 - Safety profile of 5-fluorouracil: data from the French pharmacovigilance database over a 10 year period - Manon LAUNAY (Paris)
- PS2-040 - Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with hematological malignancies - Christelle BOGLIONE-KERRIEN (Rennes)
- PS2-041 - Searching hospital database for detecting the serious consequences related to use of drugs with an abuse potential - Emilie JOUANJUS (Toulouse)
- PS2-042 - Security data about "free-access" self-medication - Malak ABOU TAAM (Reims)
- PS2-043 - Severe cardiomyopathy during anti-PD1 treatment: From French pharmacovigilance network to animal models - Frank ROUBY (Marseille)
- PS2-044 - Severe rhabdomyolysis in a patient treated with lumacaftor/ivacaftor association and aciclovir - Caroline JOYAU (Nantes)
- PS2-045 - Stent thrombosis : Report of 11 cases - Fatma Zahra BEN JEMIA (Tunis - Tunisie)
- PS2-046 - Sub-chronic toxicity of aqueous extract of Nigella sativa on Mus musculus and its antidiabetic and antioxydant effects on Rattus norvegicus - Karima BENSIAMEUR-TOUATI (Alger - Algérie)
- PS2-047 - Synthetic lysergoids : a growing family of new psychoactive substances (NPS) - Reynald LE BOISSELIER (Caen)
- PS2-048 - Tacrolimus drug monitoring during conversion from very high dose Prograf® to Advagraf® in a kidney transplant recipient - Emmanuelle MANOS (Marseille)
- PS2-049 - Target blood level of continuous infusion cyclosporine in allogeneic hematopoietic stem cell transplantation - Haifa BEN ROMDHANE (Tunis - Tunisie)
- PS2-050 - Targets for cardiovascular prevention: good use or misuse of drugs? - François GUEYFFIER (Lyon)
- PS2-051 - Text message reminders for adolescents and young adults with poorly controlled type 1 diabetes - Nour IBRAHIM (Paris)
- PS2-052 - The psychopharmacological profile of the Nigella seed oil in rats - Youness KADIL (Casablanca - Maroc)
- PS2-054 - Therapeutic Drug monitoring of Vancomycin in Pediatric Patients - Dorra BEN SAID (Tunis - Tunisie)
- PS2-055 - Thrombocytopenia associated with proton pump inhibitors: a study from the French pharmacovigilance database - Sibylle DE GERMAY (Bordeaux)
- PS2-056 - TNFalpha blockers, depression and suicidality - Nadine PETITPAIN (Nancy)
- PS2-057 - Tocilizumab (TCZ) and acne: an unexpected and potentially paradoxical side effect - Julie LEBRUN (Montpellier)
- PS2-058 - Total Flavonoids from Cydonia oblonga Mill. protect human umbilical vein endothelial cells from hydrogen peroxide induced injury and apoptosis - Ainiwaer WUMAIER (Urumqi - Chine)
- PS2-059 - Two dechlorinated chlordecone derivatives formed by in situ chemical reduction have lower genotoxicity, cytotoxicity and proangiogenic properties compared to the parent compound - Samuel LEGEAY (Angers)
- PS2-060 - Urticaria associated to contraceptive intravaginal ring : first case report and literature review - Marie-Sara AGIER (Tours)
- PS2-061 - Use of placebos in clinical practice: a survey in the elderly population in Franche-Comté Region - Marie-Blanche VALNET RABIER (Besançon)
- PS2-062 - Use of psychoactive substances by pharmacy students - Amélie DAVELUY (Bordeaux)
- PS2-063 - Validation of an in vitro hypoxia-reoxygenation model of endothelial cells: study of anti-apoptotic effects of P2 and adenosine receptors - Catherine FELIU (Reims)
- PS2-065 - Visual trouble associated with ciprofloxacin - Fatma BEN SALEM (Tunis - Tunisie)

INFORMATIONS PRATIQUES



Lieu du Congrès

Faculté de Médecine-Pharmacie
Bâtiment Stewart - Rue du Pr W-M Stewart
76000 Rouen

Dates du congrès

▪ Mercredi 19 au Vendredi 21 avril 2017

Horaires du congrès

- Mercredi 19 avril 2017 : 10h30 – 19h30 (accueil à partir de 10h00)
- Jeudi 20 avril 2017 : 8h30 – 19h30 (accueil à partir de 8h00)
- Vendredi 21 avril 2017 : 8h00 - 12h15 (accueil à partir de 8h00)

Restauration

Les pauses et déjeuners du mercredi et du jeudi sont inclus dans le tarif d'inscription et auront lieu dans l'espace exposition.

Soirée du congrès

La soirée du congrès se tiendra le jeudi 20 avril à partir de 20h00 au Panorama XXL, Quai de Boisguilbert, 14 Bis Avenue Pasteur, 76006 Rouen

Accès en tramway depuis la Faculté de Médecine – Pharmacie : à la station Martainville prendre un TEOR (T1, T2 ou T3) et descendre à l'arrêt Pasteur-Panorama.

Tarif congressiste : 55 € TTC / étudiant : 25 € TTC

Participation sur inscription – les réservations ne pourront pas se faire sur place.

Badge

Votre badge, attestation de présence et sacoche contenant les documents du congrès vous seront remis à votre arrivée à l'accueil.

Pour des raisons de sécurité, le port du badge est obligatoire pendant toute la durée du congrès.

Orateurs

Les orateurs sont invités à se présenter en salle de conférence munis d'une clé USB afin de déposer leur présentation PPT au technicien présent en salle, au moins 1 heure avant le début de la session.

WI-FI

Nom du réseau : SFPT2017

Clé de sécurité : Wiec8aiz (bien respecter la casse)

Notes

Notes

Notes

REMERCIEMENTS

La SFPT remercie ses partenaires pour l'intérêt et le soutien qu'ils ont apportés à ce congrès.



Ce projet est cofinancé par le Fonds Européen de Développement Régional (FEDER) et la Région Normandie.



Rendez-vous pour l'édition 2018 !

Du 17 au 19 avril 2018, Faculté de Médecine de Toulouse

